According to the annual review of the most expensive prescription drugs in the state, only three people dominate the list.
According to the annual review of the most expensive prescription drugs in the state, only three people dominate the list. On Thursday, the State Health Strategy Bureau announced the annual annual. Summary of the best outpatient prescription pharmacyThe state analyzes the price and use of pharmaceuticals. Every year, OHS announces a list of up to 10 drugs that meet the standards set by the state law. The drug included in the list:
- It is provided to the state at a significant cost or important for public health.
- It is expensive in the treatment process. and
- I saw a high price increase.
The analysis reviewed the price of outpatient prescription drugs as of January 1, 2022 and December 31, 2023. This year’s list does not affect drug rebates, but it contains seven drugs, which account for more than $ 555 million in commercial, medicaid and medicare advantage spending. Humira, Skyrizi, and RINVOQ, all immunosuppressants created by Abbvie Inc. accounted for 96%of the total expenditure and 95%of the total utilization included in the report. Humira, which treats arthritis, plaque psoriasis, vascular policeitis, Crohn’s disease and ulcerative colitis, accounted for almost $ 33.3 million or 65%of the total. Each of the top three drugs increased 16% of wholesale acquisition costs (WAC) between 2021-23, the report said. Amy Porter’s Amy Porter said, “It is more difficult for Connecticut residents to provide medical services required by the significant impression of prescription drugs and certain drug prices.Adds are considered special drugs, and serious or chronic people are immune or nervous or cancer. It is an expensive complex drug that requires monitoring. ”The main law has increased more than 16% for two years ago, including a drug with other therapeutic classes in an outpatient prescription list prepared by OHS every year, and more than 16% for two years ago, including the WAC (WHOLESALE BUILD COST), and more than $ 40 for the treatment process. In addition to Skyrizi and Rinvoq, this year’s list also includes an increase in costs from 18.8% to 25.5%.
